



OPEN ACCESS

EDITED AND REVIEWED BY
Zong Sheng Guo,
University at Buffalo, United States

*CORRESPONDENCE

Liwei Chen
✉ iron9999@163.com

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 14 November 2023
ACCEPTED 23 November 2023
PUBLISHED 13 December 2023

CITATION

Xie S, Wang M, Zeng C, Ou Y, Zhao L, Wang D, Chen L, Kong F and Yi D (2023) Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma. *Front. Oncol.* 13:1338060. doi: 10.3389/fonc.2023.1338060

COPYRIGHT

© 2023 Xie, Wang, Zeng, Ou, Zhao, Wang, Chen, Kong and Yi. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

Shuqi Xie[†], Mengchao Wang[†], Chuanxiu Zeng, Yan Ou, Lu Zhao, Dong Wang, Liwei Chen*, Fanming Kong and Dan Yi

Department of Oncology, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China

KEYWORDS

targeted therapy, immunotherapy, research progress, hepatocellular carcinoma, combination therapy

A Corrigendum on

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

By Xie S, Wang M, Zeng C, Ou Y, Zhao L, Wang D, Chen L, Kong F and Yi D (2023) *Front. Oncol.* 13:1197698. doi: 10.3389/fonc.2023.1197698

Text Correction

In the published article, there was an error in section 3.1.5 Pembrolizumab in combination with lenvatinib regimen

This sentence previously stated: “A multicenter, double-blind, randomized phase III LEAP-012 study showed no significant improvement in the efficacy of systemic combination TACE in combination with lenvatinib + pembrolizumab compared to TACE alone in patients with intermediate-stage HCC.”

The corrected sentence appears below:

“A multicenter, double-blind, randomized phase III LEAP-012 study is underway, which evaluates the efficacy of systemic combination TACE in combination with lenvatinib + pembrolizumab compared to TACE alone in patients with intermediate-stage HCC.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.